Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

(2021) Thomas E Lew et al.   Blood Advances

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

(2020) Sasanka M. Handunnetti et al.   BLOOD

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

(2020) Brenda J Chyla et al.   BLOOD

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

(2020) Piers Blombery et al.   BLOOD

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy

(2020) Anthony R. Mato et al.   CLINICAL CANCER RESEARCH

Clonal independence of JAK2 and CALR or MPL mutations in co-mutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing

(2020) Ella R. Thompson et al.   HAEMATOLOGICA

Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

(2019) Eugen Tausch et al.   HAEMATOLOGICA

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

(2019) Romain Guièze et al.   CANCER CELL

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia

(2018) Piers Blombery et al.   Cancer Discovery

Hypermorphic mutation of phospholipase C,  2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

(2015) T.-M. Liu et al.   BLOOD

Genomic Landscape of CXCR4 Mutations in Waldenstro m Macroglobulinemia

(2015) S. Poulain et al.   CLINICAL CANCER RESEARCH

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

(2014) V. Fresquet et al.   BLOOD

Elucidating a Key Component of Cancer Metastasis: CXCL12 (SDF-1α) Binding to CXCR4

(2014) Phanourios Tamamis et al.   Journal of Chemical Information and Modeling

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Resistance in Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists

(2010) B. Wu et al.   SCIENCE